<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26674072</article-id>
      <article-id pub-id-type="pmc">4681016</article-id>
      <article-id pub-id-type="publisher-id">1777</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-015-1777-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clozapine induced pancytopenia leading to severe sepsis: an unusual early complication</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Pushpakumara</surname>
            <given-names>Jagath</given-names>
          </name>
          <address>
            <email>jagathsltt@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Karunarathna</surname>
            <given-names>Piyumanthi</given-names>
          </name>
          <address>
            <email>piukaru@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sivathiran</surname>
            <given-names>Sivagamaroobasunthari</given-names>
          </name>
          <address>
            <email>sivagamy1980@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liyanage</surname>
            <given-names>Ajantha</given-names>
          </name>
          <address>
            <email>ajaliyanage@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Indrakumar</surname>
            <given-names>Jegarajah</given-names>
          </name>
          <address>
            <email>indrak2004@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Ward 01, Department of Medicine, University Medical Unit, Colombo South Teaching Hospital, Kalubowila, Sri Lanka </aff>
        <aff id="Aff2"><label/>Department of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>16</day>
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>792</elocation-id>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Pushpakumara et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Clozapine is a second generation antipsychotic used to treat resistant schizophrenia and other psychotic illnesses. Leucopenia or agranulocytosis is a rare side effect of this drug. Pancytopenia is an extremely rare side effect of clozapine and literature review showed only one such case in where the pancytopenia developed several months after starting clozapine together with other antipsychotic drugs.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 26-year-old Sri Lankan male was admitted with fever for 3&#xA0;days. Apart from generalized body aches there were no other significant symptoms. His blood counts showed pancytopenia. He was being treated for a resistant schizophrenia and clozapine was started only 4&#xA0;weeks before. Common causes for pancytopenia were excluded, and a diagnosis of clozapine induced pancytopenia was made. He was managed in the intensive care unit with broad spectrum antibiotics, antifungals and granulocyte colony stimulating factors. He made a complete recovery after 4&#xA0;weeks.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This is a rare and probably the first reported case of early onset clozapine induced pancytopenia complicated by severe sepsis recovering completely.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Clozapine</kwd>
        <kwd>Pancytopenia</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Clozapine is an atypical antipsychotic drug. It relieves both negative and positive symptoms of schizophrenia and is the drug of choice in resistant schizophrenia [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Clozapine causes leucopenia or agranulocytosis as a rare side effect. Clozapine induced pancytopenia is even rarer than leucopenia and review of literature showed only one published case. Agranulocytosis is defined as granulocyte count of &lt;0.5&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l, and leukopenia is defined as white blood cell (WBC) count of &lt;3.5&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l. The causes for the blood dyscrasias are believed to be due to idiosyncratic (type B) reactions, immune-mediated or toxic suppression of hemopoietic precursors due to prolonged administration [<xref ref-type="bibr" rid="CR2">2</xref>]. In our patient early occurrence of pancytopenia is most likely due to an idiosyncratic drug reaction.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 26-year-old Sri Lankan male was admitted to hospital with fever for 3&#xA0;days and body aches. He did not have any other significant symptoms. He was diagnosed of having schizophrenia 4&#xA0;years ago and was attending a psychiatric clinic. He was started on clozapine, 4&#xA0;weeks ago (200&#xA0;mg daily), because of inadequate control of symptoms with conventional antipsychotics. On examination he was febrile (102&#xA0;&#xB0;F), not pale or icteric. He did not have lymphadenopathy. Blood pressure was 130/80&#xA0;mmHg and pulse rate was 110&#xA0;bpm with good volume. His respiratory rate was 32 cycles per minute. Examination of the abdomen, cardiovascular and respiratory systems were unremarkable.</p>
      <p>His full blood count (FBC), which was done a day prior to hospital admission showed white blood cell count (WBC) 2.9&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l, absolute neutrophil count 667/&#xB5;l (23&#xA0;%), lymphocytes 2117/&#xB5;l (73&#xA0;%), Hemoglobin (Hb) 11.3&#xA0;g/dl, platelet 188&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l. The first FBC during the hospital stay showed reduced blood counts, of which WBC 0.2&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l with absolute neutrophil count (ANC) 110/&#xB5;l, lymphocyte count 80/&#xB5;l, Hb 12.2&#xA0;g/dl and platelet 972&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l. The C reactive protein was (CRP) 270&#xA0;mg/L (&lt;6&#xA0;mg/L). His chest X ray, ultrasound scan (USS) of abdomen and pelvis, urine full report was normal. Serology for dengue virus, human immunodeficiency virus and parvo B19 virus were negative. Electrocardiogram (ECG) showed sinus tachycardia.</p>
      <p>Clinical diagnosis of neutropenic sepsis was made. He was treated with intravenous imipenum, vancomycin, clindamycin, metronidazole and fluconazole. His serial blood cultures, urine cultures and sputum cultures were negative. His FBC was monitored twice daily throughout hospital stay, showed severe neutropenia and thrombocytopenia which later complicated by anemia from the 3rd day of hospital stay (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The reticulocyte count was 1.1&#xA0;% (normal 0.5&#x2013;2.5). The patient was transferred to intensive care unit (ICU) on the 3rd day and treated with granulocyte colony stimulating factors (G-CSF) 300&#xA0;&#xB5;g daily for 10&#xA0;days. On the 5th day he developed swelling of his left inguinal region with mild skin induration. The initial USS of left groin showed only subcutaneous tissue oedema. This subsequently progressed to an abscess which was drained. His white cell count and platelet count improved with 10&#xA0;days of treatment with G-CSF. Hemoglobin normalized in 4&#xA0;weeks of treatment. At this stage his WBC count was 12&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l with absolute neutrophil count 7200/&#xB5;l (60&#xA0;%), hemoglobin 12.6&#xA0;g/dl and platelets 212&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l. He was started on conventional antipsychotics without clozapine for his psychiatric condition.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Summary of the investigations during the first 18&#xA0;days of hospital stay</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Investigation</th><th align="left">D1</th><th align="left">D2</th><th align="left">D3</th><th align="left">D4</th><th align="left">D5</th><th align="left">D6</th><th align="left">D7</th><th align="left">D8</th><th align="left">D9</th><th align="left">D10</th><th align="left">D11</th><th align="left">D12</th><th align="left">D13</th><th align="left">D14</th><th align="left">D15</th><th align="left">D16</th><th align="left">D17</th><th align="left">D18</th></tr></thead><tbody><tr><td align="left">WBC (&#xD7;10<sup>3</sup>/&#x3BC;l)</td><td align="left">0.20</td><td align="left">0.32</td><td align="left">0.40</td><td align="left">0.60</td><td align="left">0.60</td><td align="left">0.80</td><td align="left">0.32</td><td align="left">0.61</td><td align="left">0.82</td><td align="left">1.0</td><td align="left">3.5</td><td align="left">9.5</td><td align="left">20</td><td align="left">27.7</td><td align="left">35.5</td><td align="left">37.2</td><td align="left">36.1</td><td align="left">29.4</td></tr><tr><td align="left">ANC (&#xD7;10<sup>3</sup>/&#x3BC;l)</td><td align="left">0.11</td><td align="left">0.10</td><td align="left">0.16</td><td align="left">0.09</td><td align="left">0.12</td><td align="left">0.14</td><td align="left">0.14</td><td align="left">0.28</td><td align="left">0.15</td><td align="left">0.34</td><td align="left">1.8</td><td align="left">6.9</td><td align="left">16.5</td><td align="left">21.6</td><td align="left">28</td><td align="left">29.6</td><td align="left">31</td><td align="left">25</td></tr><tr><td align="left">Hb (g/dl)</td><td align="left">12.2</td><td align="left">11.1</td><td align="left">10.7</td><td align="left">11.5</td><td align="left">9.6</td><td align="left">9.5</td><td align="left">8.9</td><td align="left">8.4</td><td align="left">8.7</td><td align="left">8.1</td><td align="left">8.8</td><td align="left">8.7</td><td align="left">8.3</td><td align="left">8.4</td><td align="left">8.5</td><td align="left">8.2</td><td align="left">7.1</td><td align="left">8.4</td></tr><tr><td align="left">RBC (&#xD7;10<sup>6</sup>/&#x3BC;l)</td><td align="left">4.19</td><td align="left">4.21</td><td align="left">3.95</td><td align="left">3.95</td><td align="left">4.01</td><td align="left">4.65</td><td align="left">3.56</td><td align="left">3.88</td><td align="left">4.28</td><td align="left">4.94</td><td align="left">4.22</td><td align="left">3.98</td><td align="left">4.11</td><td align="left">4.55</td><td align="left">4.82</td><td align="left">4.77</td><td align="left">4.36</td><td align="left">4.29</td></tr><tr><td align="left">MCV (fL)</td><td align="left">84</td><td align="left">85</td><td align="left">85.4</td><td align="left">85.3</td><td align="left">85.4</td><td align="left">84</td><td align="left">83.1</td><td align="left">86</td><td align="left">84.1</td><td align="left">83.1</td><td align="left">85</td><td align="left">84.2</td><td align="left">83.2</td><td align="left">85</td><td align="left">84.1</td><td align="left">86</td><td align="left">86.2</td><td align="left">85.3</td></tr><tr><td align="left">MCH (pg)</td><td align="left">32.0</td><td align="left">30.1</td><td align="left">29.8</td><td align="left">30</td><td align="left">28.8</td><td align="left">29.1</td><td align="left">31</td><td align="left">32.2</td><td align="left">31.3</td><td align="left">33</td><td align="left">34</td><td align="left">32.1</td><td align="left">33.4</td><td align="left">32</td><td align="left">34</td><td align="left">33.1</td><td align="left">33</td><td align="left">33.2</td></tr><tr><td align="left">MCHC (g/dl)</td><td align="left">34.9</td><td align="left">35.1</td><td align="left">34.9</td><td align="left">35.2</td><td align="left">33.7</td><td align="left">34.4</td><td align="left">35</td><td align="left">35.2</td><td align="left">33</td><td align="left">34</td><td align="left">33.2</td><td align="left">34</td><td align="left">33.2</td><td align="left">35</td><td align="left">35.2</td><td align="left">34.8</td><td align="left">33.8</td><td align="left">32.7</td></tr><tr><td align="left">PCV (%)</td><td align="left">35</td><td align="left">33</td><td align="left">30</td><td align="left">36</td><td align="left">28</td><td align="left">27</td><td align="left">27</td><td align="left">25</td><td align="left">25</td><td align="left">26</td><td align="left">24</td><td align="left">26</td><td align="left">26</td><td align="left">25</td><td align="left">26</td><td align="left">25</td><td align="left">22</td><td align="left">26</td></tr><tr><td align="left">Plt (&#xD7;10<sup>3</sup>/&#x3BC;l)</td><td align="left">97</td><td align="left">79</td><td align="left">53</td><td align="left">82</td><td align="left">75</td><td align="left">64</td><td align="left">70</td><td align="left">57</td><td align="left">89</td><td align="left">144</td><td align="left">196</td><td align="left">247</td><td align="left">254</td><td align="left">232</td><td align="left">212</td><td align="left">200</td><td align="left">201</td><td align="left">283</td></tr><tr><td align="left">ALT (IU/l)</td><td align="left"/><td align="left">43</td><td align="left">42</td><td align="left"/><td align="left"/><td align="left">35</td><td align="left">63</td><td align="left">58</td><td align="left">60</td><td align="left">53</td><td align="left">48</td><td align="left">56</td><td align="left">62</td><td align="left">49</td><td align="left">38</td><td align="left">23</td><td align="left"/><td align="left">30</td></tr><tr><td align="left">AST (IU/l)</td><td align="left"/><td align="left">103</td><td align="left">114</td><td align="left"/><td align="left"/><td align="left">67</td><td align="left">108</td><td align="left">70</td><td align="left">65</td><td align="left">68</td><td align="left">74</td><td align="left">80</td><td align="left">68</td><td align="left">52</td><td align="left">50</td><td align="left">65</td><td align="left"/><td align="left">42</td></tr><tr><td align="left">Alb (g/l)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">22</td><td align="left"/><td align="left"/><td align="left">23</td><td align="left"/><td align="left"/><td align="left">28</td><td align="left"/><td align="left"/><td align="left"/><td align="left">26</td><td align="left"/><td align="left"/></tr><tr><td align="left">Prot (g/l)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">44</td><td align="left"/><td align="left"/><td align="left">56</td><td align="left"/><td align="left"/><td align="left">60</td><td align="left"/><td align="left"/><td align="left"/><td align="left">60</td><td align="left"/><td align="left"/></tr><tr><td align="left">S cr (&#x3BC;mol/l)</td><td align="left"/><td align="left">56.2</td><td align="left"/><td align="left"/><td align="left"/><td align="left">71</td><td align="left">75</td><td align="left">64</td><td align="left">51</td><td align="left">47</td><td align="left"/><td align="left"/><td align="left">66</td><td align="left"/><td align="left"/><td align="left">73</td><td align="left"/><td align="left">68</td></tr><tr><td align="left">BU (mmol/l)</td><td align="left">15.7</td><td align="left">14.9</td><td align="left"/><td align="left"/><td align="left">9.3</td><td align="left">7.0</td><td align="left">6.7</td><td align="left">4.3</td><td align="left">4.3</td><td align="left">4.6</td><td align="left">3.8</td><td align="left">4.2</td><td align="left">5.0</td><td align="left">4.8</td><td align="left">3.8</td><td align="left">2.5</td><td align="left"/><td align="left"/></tr><tr><td align="left">Na<sup>+</sup> (mmol/l)</td><td align="left">134</td><td align="left">132</td><td align="left"/><td align="left"/><td align="left">140</td><td align="left">147</td><td align="left">148</td><td align="left">154</td><td align="left">132</td><td align="left">153</td><td align="left">143</td><td align="left">140</td><td align="left">138</td><td align="left">132</td><td align="left">136</td><td align="left">145</td><td align="left">138</td><td align="left">136</td></tr><tr><td align="left">K<sup>+</sup> (mmol/l)</td><td align="left">4.4</td><td align="left">3.6</td><td align="left"/><td align="left"/><td align="left">3.5</td><td align="left">3.8</td><td align="left">3.3</td><td align="left">3.4</td><td align="left">4.1</td><td align="left">5.3</td><td align="left">4.8</td><td align="left">3.9</td><td align="left">4.0</td><td align="left">3.1</td><td align="left">3.0</td><td align="left">3.2</td><td align="left">4.1</td><td align="left">4.8</td></tr><tr><td align="left">CRP (mg/l)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">270</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">30</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">34</td></tr></tbody></table><table-wrap-foot><p>
<italic>WBC</italic> white blood cells, <italic>ANC</italic> absolute neutrophil count, <italic>Hb</italic> hemoglobin, <italic>RBC</italic> red blood cell count, <italic>MCV</italic> mean corpuscular volume, <italic>MCH</italic> mean corpuscular hemoglobin, <italic>MCHC</italic> mean corpuscular hemoglobin concentration, <italic>PCV</italic> pack cell volume, <italic>Plt</italic> platelet, <italic>ALT</italic> alanine transaminase, <italic>AST</italic> aspartate transaminase, <italic>Alb</italic> albumin, <italic>Prot</italic> total protein, <italic>S cr</italic> serum creatinine, <italic>BU</italic> blood urea, <italic>Na</italic>
<sup>+</sup> serum sodium, <italic>K</italic>
<sup>+</sup> serum potassium, <italic>CRP</italic> C reactive protein</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Demonstration of pancytopenia and its recovery with the treatment</p></caption><graphic xlink:href="13104_2015_1777_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>This case illustrates an extremely rare complication of pancytopenia caused by clozapine. Clozapine is known to cause agranulocytosis or neutropenia as a rare side effect. Approximately 2.7&#xA0;% of patients treated with clozapine develop neutropenia, of which 0.9&#xA0;% develops agranulocytosis [<xref ref-type="bibr" rid="CR3">3</xref>]. Most cases (50&#x2013;80&#xA0;%) occur during 18&#xA0;weeks after commencing the treatment [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>Baseline FBC should be routinely done before commencing clozapine and total WBC should be more than 4&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l with ANC more than 2.5&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. It is recommended that weekly FBC should be done to detect blood dyscrasia early. The patient&#x2019;s WBC count, at the time of starting clozapine was 7.7&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l with ANC 3927/&#xB5;l (51&#xA0;%), lymphocytes 3080/&#xB5;l (40&#xA0;%), eosinophils 462/&#xB5;l (6&#xA0;%), and platelets 260&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l. Hematological results are reported as &#x2018;green&#x2019; (safe to continue treatment), &#x2018;amber&#x2019; (borderline low or falling result) and &#x2018;red&#x2019; (below the acceptable reference range). If the WBC subsequently drops below the &#x2018;red&#x2019; cut-off of 3&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l or the neutrophil count falls below 1.5&#xA0;&#xD7;&#xA0;10<sup>3</sup>/&#xB5;l, clozapine treatment must be stopped [<xref ref-type="bibr" rid="CR6">6</xref>]. In this patient pancytopenia was detected at 4 weeks of clozapine treatment and there were no blood counts done during this period.</p>
      <p>There was only one reported case of 57-year-old male with clozapine induced pancytopenia who was subsequently managed with electroconvulsive therapy (ECT) [<xref ref-type="bibr" rid="CR7">7</xref>]. This patient was on clozapine for several years which was later combined with fluphenazine and promazine. He developed neutropenia after 1&#xA0;year of combined antipsychotics therapy. Clozapine was stopped and restarted after 1&#xA0;year and the patient had developed pancytopenia after about one and half year of therapy. His blood counts had spontaneously improved within 7&#xA0;weeks after stopping clozapine. However In our patient the pancytopenia occurred within the first 4&#xA0;weeks of treatment initiated with with clozapine.</p>
      <p>St&#xFC;bner et al. described the blood dyscrasias induced by psychotropic drugs after analyzing 122,562 patients in 35 psychiatric institutions since 1993&#x2013;2000 [<xref ref-type="bibr" rid="CR8">8</xref>]. In this study, 107 cases of hematological changes had been documented with an incidence of 0.0873&#xA0;%. Of these, pancytopenia was seen only in 2 and rest were neutropenia (63 cases), thrombocytopenia (16 cases), agranulocytosis (22 cases) and neutropenia thrombocytopenia (4 cases). Of these 2 cases of pancytopenia, both carbamazepine and lovastatin were rated as probable causative agents in combination in one case. In the other case, pancytopenia was observed during treatment with trimipramine. Clozapine induced pancytopenia was not observed in this study.</p>
      <p>Recovery of blood dyscrasia usually occurs up to 4&#xA0;weeks after clozapine withdrawal, but there were exceptions&#x2014;in one case report thrombocytopenia and leucopenia both occurred during clozapine treatment and persisted for 13&#xA0;weeks [<xref ref-type="bibr" rid="CR7">7</xref>]. Our patient recovered successfully from clozapine induced pancytopenia within 3&#xA0;weeks. We emphasize that every patient who is started on clozapine need very close monitoring of FBC to detect blood dyscrasia to minimize serious complications.</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusion</title>
      <p>Clozapine induced pancytopenia is extremely rare and periodic FBC should be done to detect blood dyscrasia early. We report an unusual and early complication of clozapine induced pancytopenia leading to severe sepsis recovered with antibiotics, granulocyte colony stimulating factors and supportive care.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>FBC</term>
          <def>
            <p>full blood count</p>
          </def>
        </def-item>
        <def-item>
          <term>WBC</term>
          <def>
            <p>white blood cell count</p>
          </def>
        </def-item>
        <def-item>
          <term>ANC</term>
          <def>
            <p>absolute neutrophil count</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p>C reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>USS</term>
          <def>
            <p>ultra sound scan</p>
          </def>
        </def-item>
        <def-item>
          <term>ECG</term>
          <def>
            <p>electrocardiogram</p>
          </def>
        </def-item>
        <def-item>
          <term>G-CSF</term>
          <def>
            <p>granulocyte colony stimulating factors</p>
          </def>
        </def-item>
        <def-item>
          <term>ICU</term>
          <def>
            <p>intensive care unit</p>
          </def>
        </def-item>
        <def-item>
          <term>ECT</term>
          <def>
            <p>electroconvulsive therapy</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Authors&#x2019; contributions</title>
      <p>All authors were involved in the management of the patient. JP researched the background literature on the case and wrote the first draft. AL and JI contributed towards the discussions and analysis of the case. All authors read and approved the final manuscript.</p>
      <sec id="FPar1">
        <title>Authors&#x2019; information</title>
        <p>JP (MBBS) is a Registrars in Internal Medicine, PK (MBBS) is a Registrar in Hematology, SS (MBBS, MD) Senior Registrar in Internal Medicine, University Medical Unit, Colombo South Teaching Hospital, Kalubowila, Sri Lanka. AL (MBBS, MD, MRCP) is a Consultant Physician and Senior Lecturer in Medicine, JI (MBBS, MD, FRCP) is a Professor in Medicine and consultant physician, in the Department of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka.</p>
      </sec>
      <sec id="FPar2">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whiskey</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Restarting clozapine after neutropenia: evaluating the possibilities and practicalities</article-title>
          <source>CNS Drugs.</source>
          <year>2007</year>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>25</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.2165/00023210-200721010-00003</pub-id>
          <pub-id pub-id-type="pmid">17190527</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Voulgari</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clozapine-induced late agranulocytosis and severe neutropenia complicated with <italic>Streptococcus pneumonia</italic>, venous thromboembolism and allergic vasculitis in treatment-resistant female psychosis</article-title>
          <source>Case Rep Med.</source>
          <year>2015</year>
          <pub-id pub-id-type="pmid">25755670</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieberman</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Maximizing clozapine therapy, managing side effects</article-title>
          <source>J Clin Psychiatry</source>
          <year>1998</year>
          <volume>59</volume>
          <issue>3</issue>
          <fpage>38</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">9541337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmad</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rosli</surname>
              <given-names>Md</given-names>
            </name>
            <name>
              <surname>Subbiah</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maniam</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Clozapine re-challenge with lithium supplementation following clozapine-induced neutropenia</article-title>
          <source>Asian J Psychiatry.</source>
          <year>2014</year>
          <volume>15</volume>
          <issue>1</issue>
          <fpage>90</fpage>
          <lpage>92</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suraweera</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hanwella</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>de Silva</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Use of lithium in clozapine-induced neutropenia: a case report</article-title>
          <source>BMC Res Notes.</source>
          <year>2014</year>
          <volume>7</volume>
          <fpage>635</fpage>
          <pub-id pub-id-type="doi">10.1186/1756-0500-7-635</pub-id>
          <pub-id pub-id-type="pmid">25214394</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Esop</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Managing clozapine-induced neutropenia with lithium</article-title>
          <source>Psychiatr Bull</source>
          <year>2005</year>
          <volume>29</volume>
          <fpage>186</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1192/pb.29.5.186</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jovanovi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lovreti</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kuzman</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>The use of electroconvulsive therapy and general anaesthesia in catatonic schizophrenia complicated by clozapine-induced pancytopenia-case report</article-title>
          <source>Psychiatr Danub.</source>
          <year>2014</year>
          <volume>26</volume>
          <issue>3</issue>
          <fpage>285</fpage>
          <lpage>287</lpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>St&#xFC;bner</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Blood dyscrasias induced by psychotropic drugs</article-title>
          <source>Pharmacopsychiatry.</source>
          <year>2004</year>
          <volume>37</volume>
          <issue>suppl 1</issue>
          <fpage>S70</fpage>
          <lpage>S78</lpage>
          <pub-id pub-id-type="pmid">15052517</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
